SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
Date of Report: September 27, 2000
BIORA AB
SE-205 12 Malmo, Sweden
Telephone: (011) 46-40-32-13-33
Indicate by a check mark whether the registrant files or
will file annual reports under cover of Form 20-F or Form 40-F.
|X| Form 20-F |_| Form 40-F
Indicate by check mark whether the registrant by furnishing
the information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
|_| Yes |X| No
If "Yes" is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b):
Not applicable.
This Form 6-K consists of a press release issued by Biora AB
on September 27, 2000 regarding Biora increasing its focus on the dental
market.
Press release from Biora AB (publ), September 27, 2000
FOR IMMEDIATE RELEASE
NO 12/00
BIORA INCREASES ITS FOCUS ON THE DENTAL MARKET
MALMO, SWEDEN, SEPTEMBER 27, 2000 - Biora AB (NASDAQ: BIORY, SSE: BIOR)
announces today that as a step in refining the biotech company, Biora AB is
evaluating different options including selling off the BioEx part of its
R&D portfolio. The company will concentrate on indications relating to the
oral cavity.
In a commentary, Biora's President and CEO, Rickard Soderberg says:
- "As we presented in our six month report, we have already begun
financing portions of our R&D activities, that we call BioEx, using
external resources. The conditional loan of 15 million SEK from
Industrifonden for the project 'Extra oral use of Emdogain for
wound healing' was a first step within the framework of our new
strategy. We are also evaluating other opportunities to reduce the
company's future development costs, for example partnership with a
suitable pharmaceutical company that can take BioEx' research
results to the market."
Biora develops, manufactures and sells products for the treatment of
periodontal disease and for use in oral surgery. Using its proprietary
technology and expertise, Biora aims to become a world leader in
biology-based products for specialized dental therapy. Biora's American
Depository Shares are listed on the Nasdaq National Market in the US and
Biora's ordinary shares are listed on the "O-list" of the Stockholm Stock
Exchange in Sweden.
This press release may contain certain forward-looking statements that
relate to future events or future business and financial performance. Such
statements can only be predictions and the actual events or results may
differ from those discussed. The Company cautions that these statements are
subject to important factors that could cause actual results to differ
materially from those expressed or implied in such forward-looking
statements and are more fully discussed in periodic reports filed with
Securities and Exchange Commission.
------------------------------------------------------------------------------
FOR FURTHER INFORMATION, PLEASE CONTACT:
- Rickard Soderberg, President and CEO of Biora, tel: +46 (0) 703 36 13 59
- Elisabeth Lavers, Biora US-investor relations, tel: +1 203 977 7797
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
BIORA AB
Dated: September 27, 2000 By: /s/ Anders Agering
-------------------------------
Anders Agering
Chief Financial Officer
